Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides

The American Journal of Medicine
H Kobayashi

Abstract

In the investigation of the disease manifestation of DPB from the viewpoint of biofilm disease, the important factors are an excess antigen-antibody reaction in which alginate acts as the antigen and the resulting formation of immune complex. The effects of 14- and 15-membered macrolides are inhibition of immunoreaction induced by alginate and their inhibitory effect on alginate production serving as an antigen at the GMD level. Further, the specificity of macrolides on these actions was also evidenced from the standpoint of structural activity. In my opinion, based on the similarity in pathogenic process between patients with infected cystic fibrosis and patients with Pseudomonas biofilm disease, long-term administration of 14- or 15-membered ring macrolides can be tried in patients with infected cystic fibrosis.

Associated Clinical Trials

References

Jun 1, 1995·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·H KobayashiK Shimada
Jan 1, 1994·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·N Ohgaki
Nov 1, 1993·International Journal of Antimicrobial Agents·H KobayashiH Takeda

❮ Previous
Next ❯

Citations

Jul 18, 2012·Future Medicinal Chemistry·Bo Zhang, Robert Powers
Feb 16, 2000·Acta Tropica·M VorachitS Boonsong
Aug 19, 1999·Thorax·D Wales, M Woodhead
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Anne-Laure PrunierRoland Leclercq
Jul 23, 2008·Antimicrobial Agents and Chemotherapy·Mette E SkindersoeMichael Givskov
Jul 9, 2010·Clinical Microbiology Reviews·Soichiro Kanoh, Bruce K Rubin
Aug 15, 2000·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·M GuillotJ Brouard
Feb 13, 2002·Nihon rinsho. Japanese journal of clinical medicine·Arata Azuma, Shoji Kudoh
Sep 24, 2010·Future Microbiology·Christopher D SibleyMichael G Surette
Dec 8, 2010·Future Microbiology·Niels HøibyThomas Bjarnsholt
Feb 12, 2002·Pharmacotherapy·Allyson S Gaylor, Joan C Reilly
Feb 28, 2001·Microbes and Infection·N HøibyA Kharazmi
Jun 13, 1998·International Journal of Antimicrobial Agents·M T Labro
May 1, 1997·International Journal of Antimicrobial Agents·D P NicolauC H Nightingale
Sep 14, 2004·American Journal of Respiratory and Critical Care Medicine·Wan C TsaiTheodore J Standiford
Jan 20, 2005·American Journal of Respiratory and Critical Care Medicine·Pierre M BarkerBruce K Rubin
Apr 27, 2010·Paediatric Respiratory Reviews·Abdullah A Yousef, Adam Jaffe
Dec 23, 2009·Pulmonary Pharmacology & Therapeutics·Francesco BlasiEnrico Guffanti
Feb 19, 2008·International Journal of Antimicrobial Agents·Marie Tré-HardyMichel Jean Devleeschouwer
Nov 1, 2006·Revue de pneumologie clinique·M LangelotP Germaud
Jun 28, 2005·Pharmacotherapy·William A Prescott, Cary E Johnson
Mar 10, 2001·Journal of Chemotherapy·M T Labro, H Abdelghaffar
Feb 14, 2004·Clinical Otolaryngology and Allied Sciences·N FergieJ P Birchall
Oct 14, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·C R HansenH K Johansen
Jul 22, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Geraint B RogersGerd Döring
Mar 9, 2005·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Christine Rønne HansenNiels Høiby
Dec 1, 2001·FEMS Microbiology Letters·J C Hoyt, R A Robbins
Jun 24, 2004·The Annals of Pharmacotherapy·Roxane R Carr, Milap C Nahata
Sep 9, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·Kota IshizawaHidetada Sasaki
Oct 30, 2007·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Hubert O BallardLori A Shook
Mar 25, 2015·Journal of the American Society for Mass Spectrometry·Vanessa V PhelanPieter C Dorrestein
Oct 24, 2002·Current Opinion in Pulmonary Medicine·Thao NguyenMark A Gill
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Naoto Keicho, Shoji Kudoh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Kenji Nagino, Hiroyuki Kobayashi
© 2021 Meta ULC. All rights reserved